生物型主动脉瓣的结构性瓣膜衰败:一项网络Meta分析
该网络Meta分析纳入10项研究、31029例患者,比较Trifecta瓣膜与其他生物瓣膜行主动脉瓣置换术后结构性瓣膜衰败(SVD)的发生率。结果显示,与Trifecta相比,Magna Ease瓣膜的SVD或SVD再干预发生率显著更低(发生率比0.13,95%CI 0.02-0.92,P=.04);Magna Ease和Perimount的全因再干预率也显著低于Trifecta。Trifecta的SVD或SVD再干预率显著高于Magna Ease,但与Mitroflow无显著差异。
要点
- 与Trifecta相比,Magna Ease的SVD或SVD再干预发生率显著更低(发生率比0.13,95%CI 0.02-0.92)。
- Magna Ease和Perimount的全因再干预率均显著低于Trifecta。
- Trifecta的SVD或SVD再干预率显著高于Magna Ease,但与Mitroflow无显著差异。
核心结论
- Trifecta瓣膜的SVD或SVD再干预发生率显著高于Magna Ease瓣膜,但与Mitroflow瓣膜无显著差异。
- Trifecta瓣膜的全因再干预率显著高于Magna Ease和Perimount瓣膜。
- 上述发现的潜在机制需进一步研究。
研究设计与样本
- 系统文献检索比较Trifecta瓣膜与其他生物瓣膜(Perimount、Magna Ease、Mitroflow)行主动脉瓣置换术后耐久性的研究。
- 采用随机效应配对和网络Meta分析比较SVD或SVD再干预复合主要结局的发生率比。
- 共纳入10项研究、31029例患者,其中Trifecta组6832例,Perimount组19023例,Magna Ease组3514例,Mitroflow组713例。
主要发现
- 配对Meta分析中,与Trifecta相比,Magna Ease的SVD或SVD再干预发生率更低(发生率比0.13,95%CI 0.02-0.92,P=.04)。
- 网络Meta分析中,与Trifecta相比,仅Magna Ease的SVD或SVD再干预发生率显著更低(发生率比0.13,95%CI 0.02-0.97)。
- 与Trifecta相比,Magna Ease(发生率比0.18,95%CI 0.07-0.47)和Perimount(发生率比0.34,95%CI 0.12-0.98)的全因再干预率显著更低。
- 其他次要结局未发现差异。
局限性
- 原文结论指出上述发现的潜在机制需进一步研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To compare the rate of structural valve degeneration (SVD) following surgical aortic valve replacement associated with the Trifecta (TF) valve (St Jude Medical) versus other bioprosthetic valves. METHODS: A systematic literature search was conducted for studies comparing durability of the TF prosthesis to other valve types, including Perimount (Edwards Lifesciences), Carpentier-Edwards Perimount Magna Ease (ME) (Edwards Lifesciences), and Mitroflow (LivaNova USA) after surgical aortic valve replacement. Random effect pairwise and network meta-analyses were performed to compare the incident rate ratio of the composite primary outcome of SVD or reintervention due to SVD. RESULTS: Ten studies with 31,029 patients were included, of whom 6832 received TF, 19,023 received Perimount, 3514 received ME, and 713 received Mitroflow. When compared with TF, ME was associated with lower rates of SVD or reintervention for SVD (incident rate ratio, 0.13; 95% CI, 0.02-0.92; P = .04). Similarly, at network meta-analysis, when compared with TF, only ME was associated with significantly lower rates of SVD or reintervention for SVD (incident rate ratio, 0.13; 95% CI, 0.02-0.97). ME (incident rate ratio, 0.18; 95% CI, 0.07-0.47) and PM (incident rate ratio, 0.34; 95% CI, 0.12-0.98) were associated with significantly lower rate of all-cause reintervention when compared with TF. No differences in the other secondary outcomes were found. CONCLUSIONS: The TF valve is associated with significantly higher rates of SVD or reintervention for SVD than the ME valve, but not the Mitroflow valve. The TF valve was also associated with higher rates of all-cause reintervention than ME and Perimount valves. The underlying mechanism(s) of these findings warrant further investigation.
引用
- Squiers JJ, Robinson NB, Audisio K, et al. Structural valve degeneration of bioprosthetic aortic valves: A network meta-analysis. J Thorac Cardiovasc Surg. 2022. PMID: 35216819. doi:10.1016/j.jtcvs.2021.12.047
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。